SG Americas Securities LLC Reduces Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

SG Americas Securities LLC cut its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 33.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 51,974 shares of the biopharmaceutical company’s stock after selling 25,550 shares during the period. SG Americas Securities LLC’s holdings in Dynavax Technologies were worth $674,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in DVAX. Deep Track Capital LP increased its stake in shares of Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after purchasing an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C increased its stake in shares of Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock worth $66,325,000 after purchasing an additional 5,172,263 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Dynavax Technologies by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock worth $51,948,000 after purchasing an additional 171,933 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Dynavax Technologies by 1.8% during the 4th quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company’s stock worth $30,077,000 after purchasing an additional 41,000 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Dynavax Technologies by 34.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after purchasing an additional 486,981 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on DVAX shares. Wall Street Zen cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research note on Thursday, April 17th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, JMP Securities dropped their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $24.00.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $9.99 on Friday. The firm’s 50 day moving average is $10.32 and its two-hundred day moving average is $12.09. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63. The firm has a market capitalization of $1.20 billion, a P/E ratio of -19.21 and a beta of 1.06. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. Analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.